Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

NCT06326021 | Recruiting Phase 1 DMC

• 1 other identifier: BJGBYY-IIT-LCYJ-2024-004
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 4

Brief Summary

This study is a multi-center, open-label, non-randomised, single-arm phaseⅠclinical trial to explore the safety and efficacy of FL-33 CAR T therapy for refractory/relapsed acute myeloid leukaemia. The primary endpoints are incidence and type of dose limiting toxicity within 21 days of CAR T infusion; total number, incidence and severity of adverse events (AE) 30 days after CAR T infusion. The secondary endpoints are total number, incidence and severity of AEs 30 days to 2 years after CAR T infusion; objective response rate (ORR), complete response rate (CR) and complete response with incomplete haematological recovery (CRi) by dose group at 15, 30 and 90 Days after CAR T Infusion; duration of response (DOR), progression-free survival (PFS), overall survival (OS); pharmacokinetic characteristics. The trial will use BOIN12 design to explore the optimal biological dose (OBD) of FL-33 CAR T cells for refractory/relapsed acute myeloid leukaemia. FL-33 CAR T is set at two dose levels: 5\*10\^5 (±20%) CAR-T cells/kg for dose 1 (DL-1) and 1\*10\^6 (±20%) CAR-T cells/kg for dose 2 (DL-2), and after the optimal biological dose (OBD) is determined in the dose exploration phase, the dose expansion phase will expand the trial by 6-12 cases at the OBD, enrolling up to 21-27 cases. Enrolment of more than 21 cases can be reported for analysis and the trial will be stopped when enrolment reaches 27 cases.Additionally, an independent observation group was established, comprising two sequential cohorts: a minimum of 3 subjects were enrolled starting from the lowest dose level (DL-1).

Conditions

Refractory/Relapsed Acute Myeloid Leukaemia

Outcome Measures

Primary Outcomes (2)

• Dose-limiting toxicity(DLT)

  Incidence and type of dose-limiting toxicity(DLT) within 21 days of FL-33 CAR T infusion.

  21 days

• Adverse events (AEs)

  Total number, incidence and severity of adverse events (AEs) within 30 days of FL-33 CAR T infusion.

  30 days

Secondary Outcomes (6)

• Long-term Adverse events (AEs)

  From 30 days after FL-33 CAR T infusion to 2 years

• Objective Response Rate (ORR)

  15, 30, 90 days

• Duration of response (DOR)

  Up to 2 years

• Progression-free survival (PFS)

  Up to 2 years

• Overall survival (OS)

  Up to 2 years

Study Arms (4)

Autologous FL-33 CAR T

EXPERIMENTAL

Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from patients.

Drug: autologous FL-33 CAR T therapy

Prior-HSCT donor-derived FL-33 CAR T

EXPERIMENTAL

Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from prior-HSCT donors.

Drug: prior-HSCT donor-derived FL-33 CAR T therapy

Newly matched donor-derived FL33 CAR T

EXPERIMENTAL

Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from newly matched donors.

Drug: Newly matched donor-derived FL-33 CAR T therapy

FL-33-03 CAR T

EXPERIMENTAL

The independent observation group, serving as an exploratory arm, will uniformly enroll at least 3 subjects starting from the lowest dose level (DL-1) into Cohort 1 to evaluate the safety and efficacy of FL33-03 CAR-T (with TNFα inhibitor). If the results from this stage meet expectations, at least 3 additional subjects will be enrolled into Cohort 2 to evaluate the safety and efficacy of FL33-03 CAR-T (without TNFα inhibitor) at the same lowest dose level.

Drug: FL33-03 CAR-T therapy

Interventions

autologous FL-33 CAR T therapy DRUG

Autologous FL-33 CAR T cells are infused intravenously.

Autologous FL-33 CAR T

prior-HSCT donor-derived FL-33 CAR T therapy DRUG

Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.

Prior-HSCT donor-derived FL-33 CAR T

Newly matched donor-derived FL-33 CAR T therapy DRUG

Newly matched donor-derived FL-33 CAR T cells are infused intravenously

Newly matched donor-derived FL33 CAR T

FL33-03 CAR-T therapy DRUG

Optimized FL-33-03 CAR-T cells

FL-33-03 CAR T

Eligibility Criteria

• Age: 1 Year - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients diagnosed with primary resistance acute myeloid leukemia, tumour surface antigen CD33 expression, chemotherapy relapse, extramedullary relapse, persistent residual positivity or relapse/refractory after allogeneic haematopoietic stem cell transplantation;
• Age 1-70 years old;
• No severe allergies;
• Physical condition: 0-2 ECOG score;
• Expected survival ≥ 60 days;
• Bone marrow or cerebrospinal fluid tumour cells are positive for CD33 by flow cytometry assay or tumour tissues positive for CD33 by immunohistochemistry (CD33 determination of positivity: flow cytometry: \>80% of tumour cells expressing CD33 and MFI similar to normal myeloid cells is considered as full positivity; tumour cells greater than 80% of expression of CD33 but MFI lower than the CD33 expression of normal myeloid cells by 1 log is considered as low expression (dim). Tumour cells with between 20-80% positive CD33 expression are partially expressed; Pathological immunohistochemistry: tumour cells\>30% positive are considered to be positively expressed;
• Self-aware patients aged 19-70 years are required to voluntarily sign an informed consent form in writing; paediatric patients aged 1-7 years can be recruited after their legal representative (guardian) had signed an informed consent form; self-aware paediatric patients aged 8-18 years voluntarily sign an informed consent form in writing, and their legal representative (guardian) are required to sign an informed consent form in writing as well;
• Suitable and available allogeneic haematopoietic stem cell transplant donors are required, and allogeneic haematopoietic stem cell transplantation can be performed after receiving FL-33 CAR T treatment.

You may not qualify if:

• Patients who fulfil any of the following criteria may not be enrolled.
• Patients with history of allogeneic HSCT but PBMNC is not available from prior- transplant donor for preparation of CAR T cells and peripheral blood tumour load \>30%; patients without history of allogeneic HSCT and peripheral blood tumour load \>30%;
• Intracranial hypertension or cerebral impaired consciousness;
• Symptomatic heart failure or severe arrhythmia;
• Symptoms of severe respiratory failure;
• With other types of malignancy;
• Diffuse intravascular coagulation;
• Serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value;
• With sepsis or other uncontrollable infection;
• Suffering from uncontrollable diabetes mellitus;
• Severe mental disorders;
• Have significant intracranial lesions on cranial MRI;
• Organ transplantation (excluding haematopoietic stem cell transplantation) history;
• Female patients (patients of childbearing potential) with positive blood HCG test;
• Hepatitis (including hepatitis B and C) and positive screening for AIDS and syphilis.

Sponsors & Collaborators

• Beijing GoBroad Hospital: lead
• The General Hospital of Western Theater Command: collaborator
• Shanghai Liquan Hospital: collaborator
• Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai: collaborator
• Ruijin Hospital: collaborator

Study Sites (4)

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

Shanghai, Shanghai Municipality, 200435, China

NOT YET RECRUITING

Shanghai Liquan Hospital

Shanghai, Shanghai Municipality, 201418, China

NOT YET RECRUITING

The General Hospital of Western Theater Command PLA

Chengdu, Sichuan, 610083, China

NOT YET RECRUITING

BeijingGoBroadH

Beijing, China

RECRUITING

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Shaocong Miao

CONTACT

86+ 18831006667; miaosc@gobroadhealthcare.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Dept of Hemato-Oncology and Immunotherapy

Study Record Dates

• First Submitted: March 10, 2024
• First Posted: March 22, 2024
• Study Start: April 2, 2024
• Primary Completion (Estimated): June 15, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: March 10, 2026

Record last verified: 2026-03

Locations

CN (4)